GLUE — Monte Rosa Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.25bn
- $873.54m
- $123.67m
Annual income statement for Monte Rosa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 75.6 | 124 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 72.9 | 112 | 143 | 157 | 178 |
| Operating Profit | -72.9 | -112 | -143 | -81.1 | -54.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -74 | -109 | -135 | -70.1 | -39.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -74 | -109 | -135 | -72.7 | -38.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -74 | -109 | -135 | -72.7 | -38.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -74 | -109 | -135 | -72.7 | -38.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.59 | -2.3 | -2.63 | -0.984 | -0.465 |